|
1
|
Perez-Cornago A, Key TJ, Allen NE, Fensom
GK, Bradbury KE, Martin RM and Travis RC: Prospective investigation
of risk factors for prostate cancer in the UK Biobank cohort study.
Br J Cancer. 117:1562–1571. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Salinas CA, Tsodikov A, Ishak-Howard M and
Cooney KA: Prostate cancer in young men: An important clinical
entity. Nat Rev Urol. 11:317–323. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Litwin MS and Tan HJ: The diagnosis and
treatment of prostate cancer: A review. JAMA. 317:2532–2542.
2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sountoulides P and Rountos T: Adverse
effects of androgen deprivation therapy for prostate cancer:
Prevention and management. ISRN Urol. 2013(240108)2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Klarskov LL, Klarskov P, Mommsen S and
Svolgaard N: Effect of endocrine treatment on voiding and prostate
size in men with prostate cancer: A long-term prospective study.
Scand J Urol Nephrol. 46:37–43. 2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Hotte SJ and Saad F: Current management of
castrate-resistant prostate cancer. Curr Oncol. 17 (Suppl
2):S72–S79. 2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Cheng CS, Wang J, Chen J, Kuo KT, Tang J,
Gao H, Chen L, Chen Z and Meng Z: New therapeutic aspects of
steroidal cardiac glycosides: The anticancer properties of
Huachansu and its main active constituent Bufalin. Cancer Cell Int.
19(92)2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Yin PH, Liu X, Qiu YY, Cai JF, Qin JM, Zhu
HR and Li Q: Anti-tumor activity and apoptosis-regulation
mechanisms of bufalin in various cancers: New hope for cancer
patients. Asian Pac J Cancer Prev. 13:5339–5343. 2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Qiu DZ, Zhang ZJ, Wu WZ and Yang YK:
Bufalin, a component in Chansu, inhibits proliferation and invasion
of hepatocellular carcinoma cells. BMC Complement Altern Med.
13(185)2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chen Y, Guo Q, Zhang B, Kang M, Xie Q and
Wu Y: Bufalin enhances the antitumor effect of gemcitabine in
pancreatic cancer. Oncol Lett. 4:792–798. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Liu T and Huang Q: Biodegradable
brush-type copolymer modified with targeting peptide as a
nanoscopic platform for targeting drug delivery to treat
castration-resistant prostate cancer. Int J Pharm. 511:1002–1011.
2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yu CH, Kan SF, Pu HF, Jea Chien E and Wang
PS: Apoptotic signaling in bufalin- and cinobufagin-treated
androgen-dependent and -independent human prostate cancer cells.
Cancer Sci. 99:2467–2476. 2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pastor N and Cortés F: Bufalin influences
the repair of X-ray-induced DNA breaks in Chinese hamster cells.
DNA Repair (Amst). 2:1353–1360. 2003.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Han KQ, Huang G, Gu W, Su YH, Huang XQ and
Ling CQ: Anti-tumor activities and apoptosis-regulated mechanisms
of bufalin on the orthotopic transplantation tumor model of human
hepatocellular carcinoma in nude mice. World J Gastroenterol.
13:3374–3379. 2007.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hashimoto S, Jing Y, Kawazoe N, Masuda Y,
Nakajo S, Yoshida T, Kuroiwa Y and Nakaya K: Bufalin reduces the
level of topoisomerase II in human leukemia cells and affects the
cytotoxicity of anticancer drugs. Leuk Res. 21:875–883.
1997.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chang Y, Zhao Y, Zhan H, Wei X, Liu T and
Zheng B: Bufalin inhibits the differentiation and proliferation of
human osteosarcoma cell line hMG63-derived cancer stem cells.
Tumour Biol. 35:1075–1082. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Jiang Y, Zhang Y, Luan J, Duan H, Zhang F,
Yagasaki K and Zhang G: Effects of bufalin on the proliferation of
human lung cancer cells and its molecular mechanisms of action.
Cytotechnology. 62:573–583. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Chueh FS, Chen YY, Huang AC, Ho HC, Liao
CL, Yang JS, Kuo CL and Chung JG: Bufalin-inhibited migration and
invasion in human osteosarcoma U-2 OS cells is carried out by
suppression of the matrix metalloproteinase-2, ERK, and JNK
signaling pathways. Environ Toxicol. 29:21–29. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hong SH, Kim GY, Chang YC, Moon SK, Kim WJ
and Choi YH: Bufalin prevents the migration and invasion of T24
bladder carcinoma cells through the inactivation of matrix
metalloproteinases and modulation of tight junctions. Int J Oncol.
42:277–286. 2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cortés F and Piñero J: Synergistic effect
of inhibitors of topoisomerase I and II on chromosome damage and
cell killing in cultured Chinese hamster ovary cells. Cancer
Chemother Pharmacol. 34:411–415. 1994.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wethington SL, Wright JD and Herzog TJ:
Key role of topoisomerase I inhibitors in the treatment of
recurrent and refractory epithelial ovarian carcinoma. Expert Rev
Anticancer Ther. 8:819–831. 2008.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lee YC, Lee CH, Tsai HP, An HW, Lee CM, Wu
JC, Chen CS, Huang SH, Hwang J, Cheng KT, et al: Targeting of
topoisomerase I for prognoses and therapeutics of
camptothecin-resistant ovarian cancer. PloS One.
10(e0132579)2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Cuya SM, Bjornsti MA and van Waardenburg
RCAM: DNA topoisomerase-targeting chemotherapeutics: What's new?
Cancer Chemother Pharmacol. 80:1–14. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Deweese JE, Osheroff MA and Osheroff N:
DNA topology and topoisomerases: Teaching a ‘Knotty’ subject.
Biochem Mol Biol Educ. 37:2–10. 2008.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ding X, Matsuo K, Xu L, Yang J and Zheng
L: Optimized combinations of bortezomib, camptothecin, and
doxorubicin show increased efficacy and reduced toxicity in
treating oral cancer. Anticancer Drugs. 26:547–554. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Cho YS and Cho-Chung YS: Antisense protein
kinase A RIalpha acts synergistically with hydroxycamptothecin to
inhibit growth and induce apoptosis in human cancer cells:
Molecular basis for combinatorial therapy. Clin Cancer Res.
9:1171–1178. 2003.PubMed/NCBI
|
|
29
|
Griffith TS and Kemp TJ: The topoisomerase
I inhibitor topotecan increases the sensitivity of prostate tumor
cells to TRAIL/Apo-2L-induced apoptosis. Cancer Chemother
Pharmacol. 52:175–184. 2003.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wei W, Yu Y, Wang X, Yang L, Zhang H, Ji
H, Li Z, Hou J, Wu W and Guo D: Simultaneous determination of
bufalin and its nine metabolites in rat plasma for characterization
of metabolic profiles and pharmacokinetic study by
LC-MS/MS. Molecules. 24(E1662)2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Keshav R and Narayanappa U: Expression of
proliferating cell nuclear antigen (PCNA) in oral submucous
fibrosis: An immunohistochemical study. J Clin Diagn Res.
9:ZC20–ZC23. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Liu X, Xiao XY, Shou QY, Yan JF, Chen L,
Fu HY and Wang JC: Bufalin inhibits pancreatic cancer by inducing
cell cycle arrest via the c-Myc/NF-κB pathway. J Ethnopharmacol.
193:538–545. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Li Y, Tian X, Liu X and Gong P: Bufalin
inhibits human breast cancer tumorigenesis by inducing cell death
through the ROS-mediated RIP1/RIP3/PARP-1 pathways. Carcinogenesis.
39:700–707. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Li H, Hu S, Pang Y, Li M, Chen L, Liu F,
Liu M, Wang Z and Cheng X: Bufalin inhibits glycolysis-induced cell
growth and proliferation through the suppression of Integrin β2/FAK
signaling pathway in ovarian cancer. Am J Cancer Res. 8:1288–1296.
2018.PubMed/NCBI
|
|
35
|
Pan Z, Xie Y, Bai J, Lin Q, Cui X and
Zhang N: Bufalin suppresses colorectal cancer cell growth through
promoting autophagy in vivo and in vitro. RSC Advances.
8:38910–38918. 2018.
|
|
36
|
Wang Y, Lonard DM, Yu Y, Chow DC, Palzkill
TG, Wang J, Qi R, Matzuk AJ, Song X, Madoux F, et al: Bufalin is a
potent small-molecule inhibitor of the steroid receptor
coactivators SRC-3 and SRC-1. Cancer Res. 74:1506–1517.
2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhang ZJ, Yang YK and Wu WZ: Bufalin
attenuates the stage and metastatic potential of hepatocellular
carcinoma in nude mice. J Transl Med. 12(57)2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Choo GS, Lee HN, Shin SA, Kim HJ and Jung
JY: Anticancer effect of fucoidan on DU-145 prostate cancer cells
through inhibition of PI3K/Akt and MAPK pathway expression. Mar
Drugs. 14(E126)2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Bertrand R, O'Connor PM, Kerrigan D and
Pommier Y: Sequential administration of camptothecin and etoposide
circumvents the antagonistic cytotoxicity of simultaneous drug
administration in slowly growing human colon carcinoma HT-29 cells.
Eur J Cancer. 28A:743–748. 1992.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Li M, Yu X, Guo H, Sun L, Wang A, Liu Q,
Wang X and Li J: Bufalin exerts antitumor effects by inducing cell
cycle arrest and triggering apoptosis in pancreatic cancer cells.
Tumour Biol. 35:2461–2471. 2014.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Zhao H, Li Q, Pang J, Jin H, Li H and Yang
X: Blocking autophagy enhances the pro-apoptotic effect of bufalin
on human gastric cancer cells through endoplasmic reticulum stress.
Biol Open. 6:1416–1422. 2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Wu SH, Bau DT, Hsiao YT, Lu KW, Hsia TC,
Lien JC, Ko YC, Hsu WH, Yang ST, Huang YP and Chung JG: Bufalin
induces apoptosis in vitro and has Antitumor activity against human
lung cancer xenografts in vivo. Environ Toxicol. 32:1305–1317.
2017.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Zhu Z, Sun H, Ma G, Wang Z, Li E and Liu Y
and Liu Y: Bufalin induces lung cancer cell apoptosis via the
inhibition of PI3K/Akt pathway. Int J Mol Sci. 13:2025–2035.
2012.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Miao Q, Bi LL, Li X, Miao S, Zhang J,
Zhang S, Yang Q, Xie YH, Zhang J and Wang SW: Anticancer effects of
bufalin on human hepatocellular carcinoma HepG2 cells: Roles of
apoptosis and autophagy. Int J Mol Sci. 14:1370–1382.
2013.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Tu SP, Zhong J, Tan JH, Jiang XH, Qiao MM,
Wu YX and Jiang SH: Induction of apoptosis by arsenic trioxide and
hydroxycamptothecin in gastric cancer cells in vitro. World J
Gastroenterol. 6:532–539. 2000.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Liu Y, Wang X, Jia Y and Liu Y: Effects of
bufalin on the mTOR/p70S6K pathway and apoptosis in esophageal
squamous cell carcinoma in nude mice. Int J Mol Med. 40:357–366.
2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Guo F, Fan Z, Yang J, Li Y, Wang Y, Zhao
H, Xie L and Hou Z: A comparative evaluation of hydroxycamptothecin
drug nanorods with and without methotrexate prodrug
functionalization for drug delivery. Nanoscale Res Lett.
11(384)2016.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Lee EF, Harris TJ, Tran S, Evangelista M,
Arulananda S, John T, Ramnac C, Hobbs C, Zhu H, Gunasingh G, et al:
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell
survival. Cell Death Dis. 10(342)2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Hu X, Bardhan K, Paschall AV, Yang D,
Waller JL, Park MA, Nayak-Kapoor A, Samuel TA, Abrams SI and Liu K:
Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic
resistance to myeloid-derived suppressor cells and contributes to
their persistence in cancer. J Biol Chem. 288:19103–19115.
2013.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Szabó I, Bock J, Grassmé H, Soddemann M,
Wilker B, Lang F, Zoratti M and Gulbins E: Mitochondrial potassium
channel Kv1.3 mediates Bax-induced apoptosis in lymphocytes. Proc
Natl Acad Sci USA. 105:14861–14866. 2008.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Wang C and Youle RJ: The role of
mitochondria in apoptosis*. Annu Rev Genet. 43:95–118.
2009.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Er E, Oliver L, Cartron PF, Juin P, Manon
S and Vallette FM: Mitochondria as the target of the pro-apoptotic
protein Bax. Biochim Biophys Acta. 1757:1301–1311. 2006.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Zhang L, Chen D, Chen Z and Moeckel GW:
Hypertonicity-induced mitochondrial membrane permeability in renal
medullary interstitial cells: Protective role of osmolytes. Cell
Physiol Biochem. 25:753–760. 2010.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Voutsadakis IA: Apoptosis and the
pathogenesis of lymphoma. Acta Oncol. 39:151–156. 2000.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Schon EA and Giovanni M: Neuronal
degeneration and mitochondrial dysfunction. J Clin Invest.
111:303–312. 2003.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Horn HF and Vousden KH: Coping with
stress: Multiple ways to activate p53. Oncogene. 26:1306–1316.
2007.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Lankat-Buttgereit B and Göke R: The tumour
suppressor Pdcd4: Recent advances in the elucidation of function
and regulation. Biol Cell. 101:309–317. 2009.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Brady CA and Attardi LD: p53 at a glance.
J Cell Sci. 123:2527–2532. 2010.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Holley AK and St Clair DK: Watching the
watcher: Regulation of p53 by mitochondria. Future Oncol.
5:117–130. 2009.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Kuribayashi K, Krigsfeld G, Wang W, Xu J,
Mayes PA, Dicker DT, Wu GS and El-Deiry WS: TNFSF10 (TRAIL), a p53
target gene that mediates p53-dependent cell death. Cancer Biol
Ther. 7:2034–2038. 2008.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Li X, Li Z, Qiu L, Zhao C and Hu Z: Nerve
growth factor modulate proliferation of cultured rabbit corneal
endothelial cells and epithelial cells. J Huazhong Univ Sci
Technolog Med Sci. 25:575–577. 2005.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Bassili M, Birman E, Schor NF and Saragovi
HU: Differential roles of Trk and p75 neurotrophin receptors in
tumorigenesis and chemoresistance ex vivo and in vivo. Cancer
Chemother Pharmacol. 65:1047–1056. 2010.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Chen S, Guttridge DC, You Z, Zhang Z,
Fribley A, Mayo MW, Kitajewski J and Wang CY: Wnt-1 signaling
inhibits apoptosis by activating beta-catenin/T cell
factor-mediated transcription. J Cell Biol. 152:87–96.
2001.PubMed/NCBI View Article : Google Scholar
|
